Xibei Dang
Research Subjects
Xibei Dang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Aarron Willingham
Discovery Biologics, Merck & Co., Inc., South San Francisco, California 94080, United States
1 shared publicationBernhard Geierstanger
Discovery Biologics, Merck & Co., Inc., South San Francisco, California 94080, United States
1 shared publicationBhagyashree Bhagwat
Discovery Biologics, Merck & Co., Inc., South San Francisco, California 94080, United States
1 shared publicationDaniela Tomazela
Discovery Biologics, Merck & Co., Inc., South San Francisco, California 94080, United States
1 shared publicationEsther Kofman
Discovery Biologics, Merck & Co., Inc., South San Francisco, California 94080, United States
1 shared publicationFahimeh Raoufi
Discovery Biologics, Merck & Co., Inc., South San Francisco, California 94080, United States
1 shared publication
Latest Publications
- 5 September 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (18) , 16222-16234
Discovery and Evaluation of TLR-Targeted Immune Agonists
Toll-like receptor (TLR) activation converts immunologically inactive tumors into immunologically active tumors by activating tumor residing antigen-presenting cells and recruitment of cytotoxic T lymphocytes. Targeted immune agonists (TIAs) are antibody drug conjugates with small-molecule TLR agonist payloads. The mechanism of action of TIAs involves tumor antigen recognition, Fc gamma-receptor-dependent phagocytosis, and TLR-mediated activation to drive tumor killing by myeloid cells. Several new low DAR anti-HER2 TIAs conjugated with novel TLR7 or dual-TLR7/8 agonists with cleavable and noncleavable linkers were synthesized and profiled. In vitro studies demonstrated that these TIAs activate myeloid cells only in the presence of antigen-expressing cancer cells. Evaluation in ELISpot-based assays confirmed the low immunogenicity of these constructs. Systemic administration of the novel TIAs in tumor-bearing mice resulted in tumor reduction at low doses. These results provide a strong rationale for further development of the TIAs as a novel class of immunotherapeutics.
- 5 September 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (18) , 16222-16234
Discovery and Evaluation of TLR-Targeted Immune Agonists
Toll-like receptor (TLR) activation converts immunologically inactive tumors into immunologically active tumors by activating tumor residing antigen-presenting cells and recruitment of cytotoxic T lymphocytes. Targeted immune agonists (TIAs) are antibody drug conjugates with small-molecule TLR agonist payloads. The mechanism of action of TIAs involves tumor antigen recognition, Fc gamma-receptor-dependent phagocytosis, and TLR-mediated activation to drive tumor killing by myeloid cells. Several new low DAR anti-HER2 TIAs conjugated with novel TLR7 or dual-TLR7/8 agonists with cleavable and noncleavable linkers were synthesized and profiled. In vitro studies demonstrated that these TIAs activate myeloid cells only in the presence of antigen-expressing cancer cells. Evaluation in ELISpot-based assays confirmed the low immunogenicity of these constructs. Systemic administration of the novel TIAs in tumor-bearing mice resulted in tumor reduction at low doses. These results provide a strong rationale for further development of the TIAs as a novel class of immunotherapeutics.